<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0008">
 <label>8.</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Chayama</surname>
   <given-names>K</given-names>
  </string-name>, 
  <string-name>
   <surname>Takahashi</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Toyota</surname>
   <given-names>J</given-names>
  </string-name>, et al. 
  <article-title>Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</article-title>. 
  <source>
   <italic toggle="yes">Hepatology</italic>
  </source>. 
  <year>2012</year>;
  <volume>55</volume>(
  <issue>3</issue>):
  <fpage>742</fpage>â€“
  <lpage>748</lpage>. doi:
  <pub-id pub-id-type="doi">10.1002/hep.24724</pub-id>
  <pub-id pub-id-type="pmid">21987462</pub-id>
 </mixed-citation>
</ref>
